Senvelgo oral solution for cats

Senvelgo (velagliflozin oral solution) is a highly specialized veterinary pharmaceutical designed for the treatment of diabetes mellitus in cats. Developed by Boehringer Ingelheim, this medication represents a significant advancement in feline healthcare, providing an alternative to traditional insulin injections. The brand originates from Germany, founded by Albert Boehringer in the late 19th century.

Manufacturing of such technical medical products typically centralizes in the European Union, specifically within Boehringer Ingelheim's global network of production facilities across Germany, France, and Spain. As a privately held family-owned company, Boehringer Ingelheim maintains strict control over its supply chain and product development, ensuring consistent quality across international markets.